Rhodes Pharms Drug Patent Portfolio

Rhodes Pharms owns 2 orange book drugs protected by 18 US patents Given below is the list of Rhodes Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6589960 Hydromorphone and hydrocodone compositions and methods for their synthesis 09 Nov, 2020 Expired
US10039719 Methods of treating attention deficit hyperactivity disorder 16 Jun, 2020 Expired
US6419960 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020 Expired
US7083808 Controlled/modified release oral methylphenidate formulations 16 Jun, 2020 Expired
US7247318 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020 Expired
US7438930 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020 Expired
US8580310 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020 Expired
US9066869 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020 Expired
US9801823 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020 Expired
US10039719 Methods of treating attention deficit hyperactivity disorder 16 Dec, 2019 Expired
US10463624 Controlled release formulations 16 Dec, 2019 Expired
US6419960 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019 Expired
US7083808 Controlled/modified release oral methylphenidate formulations 16 Dec, 2019 Expired
US7247318 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019 Expired
US7438930 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019 Expired
US8580310 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019 Expired
US9066869 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019 Expired
US9801823 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019 Expired


Given below is the list of recent legal activities going on the following drug patents of Rhodes Pharms.

Activity Date Patent Number
Patent litigations
Expire Patent 11 Dec, 2023 US10463624
Expire Patent 07 Aug, 2023 US9066869 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 02 Aug, 2023 US9248229
Maintenance Fee Reminder Mailed 26 Jun, 2023 US10463624
Maintenance Fee Reminder Mailed 20 Feb, 2023 US9066869 (Litigated)
Expire Patent 12 Sep, 2022 US10039719
Maintenance Fee Reminder Mailed 28 Mar, 2022 US10039719
Expire Patent 06 Dec, 2021 US9801823
Maintenance Fee Reminder Mailed 21 Jun, 2021 US9801823
Payment of Maintenance Fee, 8th Year, Large Entity 22 Apr, 2021 US8580310 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 15 Feb, 2021 US9731082
Expire Patent 23 Nov, 2020 US7438930 (Litigated)
Maintenance Fee Reminder Mailed 08 Jun, 2020 US7438930 (Litigated)
Patent Issue Date Used in PTA Calculation 05 Nov, 2019 US10463624
Recordation of Patent Grant Mailed 05 Nov, 2019 US10463624


Rhodes Pharms's Family Patents


Family Patents



Rhodes Pharms Drug List

Given below is the complete list of Rhodes Pharms's drugs and the patents protecting them.


1. Aptensio Xr

Aptensio Xr is protected by 17 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039719
(Pediatric)
Methods of treating attention deficit hyperactivity disorder 16 Jun, 2020
(4 years ago)
Expired
US6419960
(Pediatric)
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020
(4 years ago)
Expired
US7083808
(Pediatric)
Controlled/modified release oral methylphenidate formulations 16 Jun, 2020
(4 years ago)
Expired
US7247318
(Pediatric)
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020
(4 years ago)
Expired
US7438930
(Pediatric)
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020
(4 years ago)
Expired
US8580310
(Pediatric)
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020
(4 years ago)
Expired
US9066869
(Pediatric)
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020
(4 years ago)
Expired
US9801823
(Pediatric)
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Jun, 2020
(4 years ago)
Expired
US10039719 Methods of treating attention deficit hyperactivity disorder 16 Dec, 2019
(4 years ago)
Expired
US10463624 Controlled release formulations 16 Dec, 2019
(4 years ago)
Expired
US6419960 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019
(4 years ago)
Expired
US7083808 Controlled/modified release oral methylphenidate formulations 16 Dec, 2019
(4 years ago)
Expired
US7247318 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019
(4 years ago)
Expired
US7438930 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019
(4 years ago)
Expired
US8580310 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019
(4 years ago)
Expired
US9066869 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019
(4 years ago)
Expired
US9801823 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations 16 Dec, 2019
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptensio Xr's drug page


2. Dilaudid

Dilaudid is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6589960 Hydromorphone and hydrocodone compositions and methods for their synthesis 09 Nov, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dilaudid's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List